


Stabilis



Droperidol



Kaubanduslikud nimed erinevates maades

Blofop	Kolumbia
Dehidrobenzoperidol	Portugal
Dehidrobenzoperidol	Araabia Ühendemiraadid, Austria, Belgia, Holland, Luksemburg, Soome, Taani
Diprivan	Argentiina, Austraalia, Austria, Belgia, Kanada, Prantsusmaa, Saudi Araabia, Tšiili
Disoprivan	Saksamaa
Dridol	Rootsi
Droleptan	Austraalia, Prantsusmaa, uus-Meremaa
Droperidol	Ameerika ühendriigid, Kanada, Maroko, Prantsusmaa, Tšiili, Ungari
Fresofol	Argentiina
Gobbifol	Argentiina
Inapsine	Ameerika ühendriigid
Profol	Argentiina
Propofol	Argentiina, Austraalia, Austria, Belgia, Kanada, Kolumbia, Tšiili
Recofol	Saudi Araabia
Sintodian	Itaalia



Stabiilsus lahustes

		0,18 mg/ml	20°C-25°C		14			1968
		0.625 mg/ml	23-27°C		180			3207



Stabiilsust mõjutavad tegurid

		0.05 mg/ml	25°C		Butorphanol tartrate : 0.08 mg/ml	15		3378
		0,05 mg/ml	25°C		Ketamine hydrochloride : 1 mg/ml Fentanyl citrate : 10 µg/ml	30		1993
		0.05 mg/ml	4°C		Butorphanol tartrate : 0.08 mg/ml	15		3378

PVC		0.05 mg/ml	25°C		Butorphanol tartrate : 0.08 mg/ml	15		3378
PVC		0,05 mg/ml	25°C		Ketamine hydrochloride : 1 mg/ml Fentanyl citrate : 10 µg/ml	30		1993
PVC		0.05 mg/ml	4°C		Butorphanol tartrate : 0.08 mg/ml	15		3378
PVC		0,05 mg/ml	4°C		Ketamine hydrochloride : 1 mg/ml Fentanyl citrate : 10 µg/ml	30		1993
PE		0,025 mg/ml	2-8°C		Tramadol hydrochloride : 1 mg/ml	32		2814
POF		0,034 mg/ml	25°C		Butorphanol tartrate : 0,067 mg/ml Ketamine hydrochloride : 1,4 mg/ml	14		4115
POF		0,034 mg/ml	4°C		Butorphanol tartrate : 0,067 mg/ml Ketamine hydrochloride : 1,4 mg/ml	14		4115
		0,052 mg/ml	20-25°C		Nefopam : 2,5 mg/ml	48		4267
		0,2 mg/ml	20°C-25°C		Morphine sulfate : 1,76 mg/ml	14		1968
		0,083 mg/ml	21-25°C		Morphine hydrochloride : 2 mg/ml	50		4929
		1,25 mg/ml	23°C		Ondansetron hydrochloride : 1 mg/ml	8		815
		0.015 & 0.075 mg/ml	25°C		Piritramide : 1.5 mg/ml	3		3188



stabiilsust mōjutavad faktorid

					1415
--	--	--	--	--	------



Sobimatus

		Droperidol : 2,5 mg/ml Aciclovir sodium : 5 mg/ml		2335
		Droperidol : 0.4 mg/ml Allopurinol sodium : 3 mg/ml		307
		Droperidol : 0.4 mg/ml Amifostine : 10 mg/ml		3
		Droperidol Amobarbital sodium		4009
		Droperidol : 2.5 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Droperidol : 2.5 mg/ml Azithromycine : 2 mg/ml		1800
		Droperidol : 0.4 mg/ml Aztreonam : 40 mg/ml		99
		Droperidol : 2.5 mg/ml Bivalirudin : 5 mg/ml		1713
		Droperidol : 0,05 mg/ml Butorphanol tartrate : 0,08 mg/ml		3378
		Droperidol : 2.5 mg/ml Caffeine : 10 mg/ml		3964

		Droperidol : 2.5 mg/ml Cefmetazole sodium : 100 mg/ml		93
		Droperidol : 2,5 mg/ml Cimetidine hydrochloride : 150 mg/ml		1438
		Droperidol : 0.4 mg/ml Cladribine : 0.015 mg/ml		1496
		Droperidol : 0.4 mg/ml Cladribine : 0.5 mg/ml		1496
		Droperidol : 2.5 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Droperidol : 0.4 mg/ml Docetaxel : 0.9 mg/ml		1754
		Droperidol : 2,5 mg/ml Doxorubicin hydrochloride : 2 mg/ml		763
		Droperidol : 0.4 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Droperidol : 0.4 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Droperidol		4009
		Droperidol : 2.5 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Droperidol Cisatracurium besylate		3601
		Droperidol : 2,5 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Droperidol : 0.4 mg/ml Famotidine : 2 mg/ml		215
		Droperidol : 2.5 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Droperidol : 2.5 mg/ml Fluconazole : 2 mg/ml		496
		Droperidol Fluorouracil		3474
		Droperidol : 2,5 mg/ml Folinate calcium : 10 mg/ml		763
		Droperidol : 2.5 mg/ml Furosemide : 10 mg/ml		1088
		Droperidol : 0.4 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Droperidol Heparin sodium		3540
		Droperidol : 1.25 mg/ml Heparin sodium : 1 UI/ml		1228
		Droperidol : 2,5 mg/ml Heparin sodium : 1000 UI/ml		763
		Droperidol : 0.4 mg/ml		301
		Droperidol : 2.5 mg/ml Foscarnet sodium : 24 mg/ml		73
		Droperidol Glycopyrronium bromide		3599
		Droperidol : 0.4 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182

		Droperidol : 0.4 mg/ml		1415
		Droperidol : 0.4 mg/ml Filgrastim : 30 µg/ml		244
		Droperidol : 0.4 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Droperidol : 2,5 mg/ml Fluorouracil : 50 mg/ml		763
		Droperidol : 2,5 mg/ml Furosemide : 10 mg/ml		763
		Droperidol : 1.25 mg/ml Heparin sodium : 1 UI/ml	RL	1228
		Droperidol : 1.25 mg/ml Heparin sodium : 1 UI/ml		1228
		Droperidol : 2.5 mg/ml Hetastarch : 60 mg/ml		1721
		Droperidol : 1.25 mg/ml Hydrocortisone sodium succinate : 1 mg/ml	RL	1228
		Droperidol : 1.25 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		1228
		Droperidol : 1.25 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		1228
		Droperidol : 0.04 & 2.5 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Droperidol : 0.4 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Droperidol : 0.4 mg/ml Linezolid : 2 mg/ml		1925
		Droperidol : 0,05 mg/ml Lornoxicam : 0,4 mg/ml		4429
		Droperidol : 0.4 mg/ml Melphalan : 0.1 mg/ml		169
		Droperidol Methohexital sodium		4009
		Droperidol : 2,5 mg/ml Methotrexate sodium : 25 mg/ml		763
		Droperidol : 2.5 mg/ml Methotrexate sodium : 25 mg/ml		1088
		Droperidol Methotrexate sodium		3637
		Droperidol : 2,5 mg/ml Metoclopramide hydrochloride : 5 mg/ml		763
		Droperidol : 1.25 mg/ml Midazolam hydrochloride : 2.5 mg/ml		404
		Droperidol Mivacurium chloride		4993
		Droperidol : 2.5 mg/ml N-acetylcysteine : 200 mg/ml		3766
		Droperidol : 2.5 mg/ml Nafcillin sodium : 33 mg/ml		1366
		Droperidol : 2,5 & 5 mg/ml Nalbuphine hydrochloride : 5 & 10 mg/ml		616

		Droperidol : 2.5 mg/ml Naloxone hydrochloride : 0.4 mg/ml	Ø	3408
		Droperidol : 0,052 mg/ml Nefopam : 2,5 mg/ml	▲	4267
		Droperidol : 0.4 mg/ml Ondansetron hydrochloride : 1 mg/ml	▲	334
		Droperidol : 1.25 mg/ml Ondansetron hydrochloride : 1 mg/ml	▲	815
		Droperidol : 2,5 mg/ml Oxaliplatin : 0,5 mg/ml	◆	1662
		Droperidol : 0.4 mg/ml Paclitaxel : 1.2 mg/ml	◆	248
		Droperidol : 2.5 mg/ml Pemetrexed disodium : 20 mg/ml	▲	1953
		Droperidol Pentobarbital sodium		4009
		Droperidol : 2.5 mg/ml Pethidine hydrochloride : 10 mg/ml	◆	62
		Droperidol Phenobarbital sodium		4009
		Droperidol : 0.4 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml	◆	81
		Droperidol : 1.25 mg/ml Potassium chloride : 40 mEq/l	◆	1228
		Droperidol : 1.25 mg/ml Potassium chloride : 40 mEq/l	RL	1228
		Droperidol : 1.25 mg/ml Potassium chloride : 40 mEq/l	▲	1228
		Droperidol : 0.4 mg/ml Propofol : 10 mg/ml	Ø	300
		Droperidol : 2.5 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml	▲	59
		Droperidol : 0.4 mg/ml Sargramostim : 10 µg/ml	▲	335
		Droperidol : 0.4 mg/ml Teniposide : 0.1 mg/ml	◆	905
		Droperidol Thiopental sodium		4009
		Droperidol : 0.4 mg/ml Thiotepa : 1 mg/ml	◆	249
		Droperidol : 0,025 mg/ml Tramadol hydrochloride : 1 mg/ml	◆	2814
		Droperidol : 2,5 mg/ml Vinblastine sulfate : 1 mg/ml		763
		Droperidol : 2,5 mg/ml Vincristine sulfate : 1 mg/ml		763
		Droperidol : 0.4 mg/ml Vinorelbine tartrate : 1 mg/ml	▲	84



Manustamis viis



Viited

	tüüp	avaldamine
3	ajaleht	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	ajaleht	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	ajaleht	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
73	ajaleht	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	ajaleht	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	ajaleht	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
93	ajaleht	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	ajaleht	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	ajaleht	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	ajaleht	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
215	ajaleht	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
244	ajaleht	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	ajaleht	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.

249	ajaleht	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	ajaleht	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
299	ajaleht	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	ajaleht	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	ajaleht	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	ajaleht	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	ajaleht	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	ajaleht	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
404	ajaleht	Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299.
491	ajaleht	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	ajaleht	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	ajaleht	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
616	ajaleht	Jump WG, Plaza VM, Poremba A. Compatibility of nalbuphine hydrochloride with other preoperative medications. Am J Hosp Pharm 1982 ; 39: 841-843.
763	ajaleht	Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
815	ajaleht	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
905	ajaleht	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.

921	ajaleht	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1088	ajaleht	Johnston A, McKenzie MA, Krasnow SH, Hood MA, Cohen MH. Drug trapping in intravenous infusion side arms. JAMA 1984 ; 252: 2392.
1228	ajaleht	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
1366	ajaleht	Jeglum EL, Winter E, Kotos M. Nafcillin sodium incompatibility with acidic solutions. Am J Hosp Pharm 1981 ; 38: 462,464.
1410	ajaleht	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	ajaleht	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	ajaleht	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1438	ajaleht	Souney PF, Solomon MA, Stancher D. Visual compatibility of cimetidine hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1984 ; 41: 1840-1841.
1496	ajaleht	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	ajaleht	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	ajaleht	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	ajaleht	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	ajaleht	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	ajaleht	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	ajaleht	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1800	ajaleht	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	ajaleht	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.

1925	ajaleht	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	ajaleht	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1968	ajaleht	Williams OA, Middleton M, Henderson P, Reilly CS. Stability of morphine and droperidol separately and combined, for use as an infusion. Hosp Pharm Pract 1992 ; 2, 9: 597-600.
1993	ajaleht	Lee DKT, Wang DP, Harsono R, Wong CY. Compatibility of fentanyl citrate, ketamine hydrochloride, and droperidol in 0.9% sodium chloride injection stored in polyvinyl chloride bags. Am J Health-Syst Pharm 2005 ; 62: 1190-1192.
2335	ajaleht	Canann D, Tyler L.S, Barker B, Condie C. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
2814	ajaleht	Lebitasy M, Hecq JD, Vanbeckbergen D, Jamart J, Galanti L. Long-term stability of tramadol hydrochloride and droperidol mixture in 5% dextrose infusion polyolefin bags at 5 +/- 3°C. Ann Pharm Fr 2009 ; 67: 272-277.
3012	ajaleht	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3188	ajaleht	Selbach S, Diederich WE, Fett, Fründ SD, Koch T, Eberhart LHJ. Stability indicating HPLC assay for the determination of piritramide and droperidol in PCA solutions. J Clin Pharm Ther 2011 ; 36, 2: 161-165.
3207	ajaleht	McCluskey Susan V, Lovely Jenna K . Stability of Droperidol 0.625 mg/mL Diluted with 0.9% Sodium Chloride Injection and Stored in Polypropylene Syringes. Int J Pharm Compound 2011 ; 15, 2: 170-173.
3378	ajaleht	Chen F-C, Fang B-X, Li P, Yang J-G, Zhou B-H. Compatibility of butorphanol and droperidol in 0.9% sodium chloride injection Am J Health-Syst Pharm 2013 ; 70:515-519.
3408	ajaleht	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3474	Labor	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3540	Labor	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3599	Labor	Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics Amco Amdipharm Mercy 2013
3601	Labor	Cisatracurium Actavis - Résumé des Caractéristiques du Produit Actavis 2012
3637	Labor	Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics Hameln Pharmaceuticals 2014
3766	ajaleht	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3964	ajaleht	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.

4009	Labor	Droperidol - Résumé des Caractéristiques du Produit
4115	ajaleht	Pang H, Wang Q, Gu J, Chen F, Shi X. Physicochemical stability of ternary admixtures of butorphanol, ketamine, and droperidol in polyolefin bags for patient-controlled analgesia use. Drug Design Dev Ther 2016 ;10:3873-3878
4267	ajaleht	D'Huart E, Vigneron J, Clarot I, Demoré B. Physicochemical stability of nefopam and nefopam/droperidol solutions in polypropylene syringes for intensive care units. EJHP 2019
4429	ajaleht	Fang B-X, Li P, Shi X-Y, Chen F.C, Wang L.H. Incompatibilities of lornoxicam with 4 antiemetic medications in polyolefin bags during simulated intravenous administration. Medicine 2016 ; 95:25(e3824)
4929	ajaleht	Nobels A, Closset M, Bihin B, Jamart J, Soumoy L, Lombet L, Hecq JD, Galanti L, Colsoul ML, Catry E. Long-term Physicochemical Stability of a Pharmaceutical Preparation of Morphine Hydrochloride and Droperidol in Polypropylene Syringes. Int J Pharm Compound 2025 ;29,2:141-149
4993	Labor	MIVACRON 20 mg/10 ml, solution injectable (IV) - Résumé des caractéristiques du produit. ASPEN PHARMA TRADING LIMITED



Sõnaraamat

	neuroleptikum		Süsteravim
	Kaubanduslikud nimed erinevates maades		Stabiilsus lahustes
	konteiner		Molekul
	kontsentratsioon		temperatuur
	ladustamine		Stabiilsuse kestus
	biosimilar		vastuolulisi andmeid
	Viited		süstal polüpropüleenist
	naatriumkloriid 0.9%		valgus
	päev		kaitsta valguse eest
	Stabiilsust mõjutavad tegurid		lahusti
	ingredient		klaas
	polüvinüülkloriid		polüetüleen
	glükoos 5%		polüolefiin
	Tund		stabiilsust mõjutavad faktorid
	Parenteraalse toitmise (lipiidide)		indutseerib
	degradatsioon		Sobimatus
	Ühilduv		Kohene sade
	Sobimatu		Täpsustamata sobimatus
	Sade 4 tunni pärast		mitte ükski
	süstevesi		NaCl 0,9%+ apürogeenne vesi
	Parenteraalse toitmise (lipiide tasuta)		Emulsiooni ebastabiilsus 1 tunni pärast
RL	Ringer laktaat		konkreetsed lahusti
	Sademed 24 tunni pärast		Manustamis viis
	intravenoosne		intravenoosne infusioon
	pidevinfusioon		intramuskulaarne
	subkutaanne		Viited
	Sõnaraamat		